ReviewLeukemia & lymphoma2017
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Review in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Efficacy of 10-day decitabine in acute myeloid leukemia.Leukemia research · 2021Trial
- Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.Haematologica · 2019Trial
- Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.Blood advances · 2018Trial
- Potential diagnostic, prognostic, and therapeutic implications of ferroptosis in myelodysplastic syndromes.Discover oncology · 2026Review
- DNMT3A in cancer: from epigenetic writer to oncogenic driver.Clinical epigenetics · 2026Review
- DNA methyltransferase inhibitors in hematological malignancies and solid tumors.International journal of cancer · 2026Review
- From mutation to medication: iadademstat and the next era in MDS targeted therapy.Annals of medicine and surgery (2012) · 2025Article
- Targeted and epigenetic therapies for acute myeloid leukemia treatment.Discover oncology · 2025Review
- GSK-3484862, a DNMT1 degrader, promotesNAR cancer · 2025Article
- A Comprehensive Review on Novel Pathways in Cancer Treatment: Clinical Applications and Future Prospects.Current cancer drug targets · 2025Review
- Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.International journal of molecular sciences · 2024Article
- Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.Science advances · 2024Article
- New prospects of cancer therapy based on pyroptosis and pyroptosis inducers.Apoptosis : an international journal on programmed cell death · 2024Review
- Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.Therapeutic advances in hematology · 2024Article
- Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article.Global medical genetics · 2023Review
- How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.Clinical hematology international · 2023Review
- Are We Ready For "Triplet" Therapy in Higher-Risk MDS?Clinical hematology international · 2023Article
- Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells.PloS one · 2023Article
- Pyroptosis: the dawn of a new era in endometrial cancer treatment.Frontiers in oncology · 2023Review
- The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.Journal of hematology & oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.